Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaborations with Dow AgroSciences and Ardent Mills LLC to develop and commercialize wheat varieties. The company was founded in 2002 and is headquartered in Davis, California.
Industry, Sector and Symbol
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Phone530-756-7077
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.03 million
Profitability
Miscellaneous
Employees42
Next Earnings Date3/27/2019 (Confirmed)
OptionableNot Optionable
Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions
What is Arcadia Biosciences' stock symbol?
Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."
When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?
Arcadia Biosciences's stock reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.
How were Arcadia Biosciences' earnings last quarter?
Arcadia Biosciences Inc (NASDAQ:RKDA) announced its quarterly earnings results on Friday, August, 10th. The basic materials company reported ($2.02) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.29) by $0.73. The basic materials company earned $0.44 million during the quarter, compared to analyst estimates of $0.20 million. Arcadia Biosciences had a negative net margin of 645.18% and a negative return on equity of 302.21%. View Arcadia Biosciences' Earnings History.
When is Arcadia Biosciences' next earnings date?
What price target have analysts set for RKDA?
1 equities research analysts have issued 12-month target prices for Arcadia Biosciences' stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Arcadia Biosciences' share price to reach $20.00 in the next year. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for Arcadia Biosciences.
What is the consensus analysts' recommendation for Arcadia Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcadia Biosciences.
What are Wall Street analysts saying about Arcadia Biosciences stock?
Here are some recent quotes from research analysts about Arcadia Biosciences stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation utilizes a discounted cash flow-based approach that derives a $140M value for RS Wheat, using a 15% discount rate, 30% tax rate and 10% manufacturing spend." (2/28/2019)
- 2. According to Zacks Investment Research, "Arcadia Biosciences, Inc. is engaged in developing and commercializing agricultural products primarily in the United States. The Company's product includes nitrogen use crops, salt tolerant plants, sunflower oil and shelf-life produce. Arcadia Biosciences, Inc. is headquartered in Davis, California. " (2/14/2019)
Has Arcadia Biosciences been receiving favorable news coverage?
Press coverage about RKDA stock has been trending somewhat positive on Saturday, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcadia Biosciences earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the basic materials company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days.
Who are some of Arcadia Biosciences' key competitors?
What other stocks do shareholders of Arcadia Biosciences own?
Who are Arcadia Biosciences' key executives?
Arcadia Biosciences' management team includes the folowing people:
- Mr. Rajendra Ketkar, Pres, CEO & Director (Age 65)
- Mr. Matthew T. Plavan, CFO, Sec. & Pres of Arcadia Specialty Genomics (Age 55)
- Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 53)
- Ms. Sarah Reiter, Chief Commercial Officer (Age 47)
When did Arcadia Biosciences IPO?
(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.
Who are Arcadia Biosciences' major shareholders?
Arcadia Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.84%). Company insiders that own Arcadia Biosciences stock include Eric J Rey and Zhongjin Lu. View Institutional Ownership Trends for Arcadia Biosciences.
Which major investors are selling Arcadia Biosciences stock?
RKDA stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Arcadia Biosciences company stock in the last year include Eric J Rey and Zhongjin Lu. View Insider Buying and Selling for Arcadia Biosciences.
How do I buy shares of Arcadia Biosciences?
Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcadia Biosciences' stock price today?
One share of RKDA stock can currently be purchased for approximately $7.20.
How big of a company is Arcadia Biosciences?
Arcadia Biosciences has a market capitalization of $34.38 million and generates $4.03 million in revenue each year. The basic materials company earns $-15,700,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Arcadia Biosciences employs 42 workers across the globe.
What is Arcadia Biosciences' official website?
How can I contact Arcadia Biosciences?
Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]
MarketBeat Community Rating for Arcadia Biosciences (NASDAQ RKDA)
MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote "Outperform" if you believe RKDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
